CAMBRIDGE, Mass.--Millennium Pharmaceuticals has launched a strategic initiative to build a network of clinical research alliances to enhance its drug discovery, development, and predictive medicine efforts, the company said. Research collaborations of three years each with the University of Texas M.D. Anderson Cancer Center and the University of Pittsburgh are expected to provide Millen nium with clinical expertise and access to clinical samples and tissue collections. Millen nium said the alliances will broaden its capabilities in the large scale identification and characterization of novel gene targets and markers important for the prognosis, diagnosis, and treatment of major human diseases.
Millennium's collaboration with M.D. Anderson focuses on the collection of information derived from clinical samples and tissue collections in the field of oncology.
The collaboration with the University of Pittsburgh Medical Center Health System aims to develop a comprehensive tissue bank and informatics resources to further the understanding of human disease processes and facilitate the identification of molecular targets, Millennium said.